There are now a number of other drugs in the same class in different stages of development, which have been shown to be even more potent inhibitors of hepatitis B replication. The large experience ...

Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

For many people, the immune system is able to take control over the virus and they produce antibodies to one of the proteins of hepatitis B called ‘e’-antigen (or HBeAg). The amount of viral ...

Hepatitis B virus (HBV) infection is associated with liver diseases, including chronic hepatitis, which notably increases the risk of cirrhosis and hepatocellular carcinoma (HCC) development. Although ...

The aims of hepatitis B treatment include stopping hepatitis B virus replication, reducing liver inflammation, and lowering the risk of developing cirrhosis or liver cancer. Antiviral medications ...

Currently, there is no feline vaccine for the hepatitis B virus, and the hepatitis B vaccine for humans is highly toxic to ...

Despite numerous treatment advances, chronic hepatitis B virus (HBV) infection remains ... an immune system response and suppressing viral replication to protect healthy hepatocytes may result ...

Scientists from the Institut Pasteur, in collaboration with Kumamoto University in Japan, have assessed a new rapid diagnostic test to identify pregnant women at elevated risk of transmitting ...

Thomas Jeffries does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...

Hepatitis B is a lifelong infection of the liver caused ... traditional therapeutics for most patients - can inhibit viral replication and bring hepatitis under control, but they cannot eradicate ...